Nutcracker Therapeutics

We can't believe it's September already! Over the last several months, our team members presented on our engineered transmembrane immunomodulator, ENG-LIGHT; our mRNA therapeutic for prostate cancer, NTX-470; our latest therapeutic program for B-cell autoimmune and lymphoma diseases, NTX-472; new methods of delivery for oncology therapeutics; our CodonCracker™ software; and analytical control strategies for the production of quality mRNA. 

It's Blood Cancer Awareness Month! Every year more than 1 million individuals are diagnosed with a blood cancer, globally.* This month aims to educate and bring much-needed recognition to blood cancer and those that are affected by it. We're developing NTX-472, our latest candidate to encode for a multi-specific antibody targeting CD19, CD20 and CD47 for B-cell autoimmune and lymphoma diseases. #BloodCancer *https://lnkd.in/gjBE-J4D

It's estimated that 1 in 44 men will die of prostate cancer in the U.S.* It's important to increase awareness of prostate cancer and support those who are affected by it. We're developing our tri-specific mRNA drug candidate, NTX-470, as a therapeutic option for castration-resistant prostate cancer. *https://lnkd.in/g5CSr93x

We're excited to be at the RNA Leaders USA Congress in San Diego this week! Babak Sanii will be giving a talk in room 6F on microfluidic characteristics that enable the rapid manufacturing of personalized cancer vaccines. We hope to see you there!

We're thrilled to announce that our peer-reviewed paper, “Discovery of a peptoid-based nanoparticle platform for therapeutic mRNA delivery via diverse library clustering and structural parameterization,” has been published in ACS Nano! Congratulations to the team for your great work! Read the paper here: https://lnkd.in/e3_5DR5z.  Read the press release here: https://lnkd.in/ecSpC5Hf

We recently spoke with Clinical Supply Leader about the scale-up process in RNA manufacturing. Read the article here: https://lnkd.in/etxqHHNE

We're excited to be back in Boston this week at the 3rd Annual Next Generation Lipid-Based Nanoparticles Delivery Summit! Nicole Peck, Senior Scientist, will be giving a talk titled: "Peptoid-Based Nanoparticle Delivery of mRNA Therapeutics." We'd love to see you there!

August is National Immunization Awareness Month! Vaccination rates have fallen since the pandemic, including vaccination against HPV.* NTX-250, our lead candidate, is designed to destroy cancerous and precancerous growths on the cervix while also clearing out the causative HPV infection. *https://lnkd.in/eGiPfTZr

We're thrilled to be sponsoring the 12th Annual Peptoid Summit in Berkeley, California this week! Elizabeth W., Senior Scientist, will be giving a talk titled: "Tunable Peptoid-based Nanoparticle Delivery Platform for mRNA Therapeutics," and Wei-Lun Tang, Scientist II, will also be attending.

We're so excited that Evan McCartney-Melstad, Director of Informatics, will be be leading a roundtable discussion on Optimizing Structure-Based Drug Design with Machine Learning at the AI in Drug Discovery Xchange in San Francisco next month! Learn more here: https://lnkd.in/eqedPVZM